Tags

Type your tag names separated by a space and hit enter

Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Alzheimers Dement. 2015 Aug; 11(8):986-93.AD

Abstract

BACKGROUND

We evaluated the relationship between florbetapir-F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers.

METHODS

Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression.

RESULTS

In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p-tau added discriminative power to FBP PET when classifying HC versus AD.

CONCLUSION

Based on cross-sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.

Authors+Show Affiliations

Eli Lilly and Company, Indianapolis, IN, USA; Department of Neurology Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: hakean@lilly.com.Eli Lilly and Company, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana University Health Physicians Group, Indiana University Health, Indianapolis, IN, USA.Eli Lilly and Company, Indianapolis, IN, USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25916563

Citation

Hake, Ann, et al. "Florbetapir Positron Emission Tomography and Cerebrospinal Fluid Biomarkers." Alzheimer's & Dementia : the Journal of the Alzheimer's Association, vol. 11, no. 8, 2015, pp. 986-93.
Hake A, Trzepacz PT, Wang S, et al. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimers Dement. 2015;11(8):986-93.
Hake, A., Trzepacz, P. T., Wang, S., Yu, P., Case, M., Hochstetler, H., Witte, M. M., Degenhardt, E. K., & Dean, R. A. (2015). Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 11(8), 986-93. https://doi.org/10.1016/j.jalz.2015.03.002
Hake A, et al. Florbetapir Positron Emission Tomography and Cerebrospinal Fluid Biomarkers. Alzheimers Dement. 2015;11(8):986-93. PubMed PMID: 25916563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. AU - Hake,Ann, AU - Trzepacz,Paula T, AU - Wang,Shufang, AU - Yu,Peng, AU - Case,Michael, AU - Hochstetler,Helen, AU - Witte,Michael M, AU - Degenhardt,Elisabeth K, AU - Dean,Robert A, AU - ,, Y1 - 2015/04/24/ PY - 2014/03/28/received PY - 2015/01/16/revised PY - 2015/03/06/accepted PY - 2015/4/29/entrez PY - 2015/4/29/pubmed PY - 2016/5/6/medline KW - Alzheimer's Disease Neuroimaging Initiative KW - Alzheimer's disease KW - Biomarkers KW - Cerebrospinal fluid KW - Florbetapir positron emission tomography KW - Mild cognitive impairment SP - 986 EP - 93 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 11 IS - 8 N2 - BACKGROUND: We evaluated the relationship between florbetapir-F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers. METHODS: Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression. RESULTS: In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p-tau added discriminative power to FBP PET when classifying HC versus AD. CONCLUSION: Based on cross-sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed. SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/25916563/Florbetapir_positron_emission_tomography_and_cerebrospinal_fluid_biomarkers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1552-5260(15)00119-3 DB - PRIME DP - Unbound Medicine ER -